Marizyme, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 04:28 pm EST
Share
Marizyme, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.181535 million compared to USD 0.076012 million a year ago. Net loss was USD 32.45 million compared to USD 1.55 million a year ago. Basic loss per share from continuing operations was USD 0.71 compared to USD 0.04 a year ago.
For the nine months, sales was USD 0.495248 million compared to USD 0.137821 million a year ago. Net loss was USD 55.58 million compared to USD 14.6 million a year ago. Basic loss per share from continuing operations was USD 1.28 compared to USD 0.36 a year ago.
Marizyme, Inc. is a multi-technology life science company. The Company is engaged in the development and commercialization of medical technologies that improves patient health outcomes. Its products include DuraGraft, MATLOC 1 and Krillase. DuraGraft is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery. MATLOC is a lab-on-chip digital screening and diagnostic device platform, which is being developed for quantitative chronic kidney disease (CKD) assessment. Krillase can be used in the treatment of chronic wounds and burns, and other clinical applications. Its DuraGraft is an endothelial damage inhibitor (EDI), indicated for cardiac bypass, peripheral bypass, and other vascular surgeries.
MARIZYME, INC. 
